ATRA · Atara Biotherapeutics, Inc. · Analyst Estimates
$7.93
-0.30 (-3.65%)
At close · Nov 12
Return incl. dividend (before tax)
Q3 2023 earnings call transcript
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$80.79M
Shares
10.19M
Volume · Nov 12
16.7K
Avg daily vol (3M)
38.48K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Atara Biotherapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-13 04:59 UTC · Publication dates shown per estimate · 6 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.27
|
-0.95
|
-0.63
|
2
|
-1.27
|
-0.88
|
-0.88
|
-1.23
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
1.15M
|
2.85M
|
5.00M
|
3
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
0.53
|
1.55
|
2.56
|
2
|
1.57
|
1.27
|
1.27
|
1.64
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
31.00M
|
40.87M
|
57.00M
|
3
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.33
-0.32
|
-0.22
-0.19
|
-0.06
0.00
|
2
0
|
-0.33
-0.32
|
-0.21
-0.18
|
-0.21
-0.18
|
-0.30
-0.29
|
0
0
|
0
0
|
0
0
|
0
0
|
|
Revenue
USD
Publication date not stated |
0.00
700,000.00
|
533,330.00
700,000.00
|
1.00M
700,000.00
|
3
1
|
— | — | — | — | — | — | — | — |
Key facts
CIK
1604464
CUSIP
046513206
13F (30d)
31 filings
18 filers
Visit website
Investor relations